← Leaderboards
Lia Gore
University Of Colorado Denver
$388,701
Attributed
$388,701
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $357K · FY2005–15$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$388,701 · 4
By mechanism
T32$356,968 · 1
M01$31,733 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Paul A Bunn$21,859,370
- Karen L Kelly$2,781,251
- Douglas K Graham$6,579,169
- Jean Marie Mulcahy Levy$2,536,082
- Nina S Kadan-Lottick$5,510,109
Others in their field
Top investigators on “17-(Allylamino)-17-Demethoxygeldanamycin”
- Neal Rosen · Sloan-Kettering Institute For Cancer Res$4,351,941
- Brian S J Blagg · Scripps Research Institute$4,276,284
- Paul Dent · Virginia Commonwealth University$3,497,727
- Kapil N. Bhalla · University Of Tx Md Anderson Can Ctr$3,278,249
- Kathleen Louise Gabrielson · Johns Hopkins University$2,314,945
- Joan Massague · Sloan-Kettering Institute For Cancer Res$2,266,124
Research focus
17-(Allylamino)-17-DemethoxygeldanamycinAdult LeukemiaBaseCancer CellChildhoodChildhood Solid NeoplasmComputer Retrieval Of Information On Scientific Projects DatabaseCorrelative StudyDiagnosisDoseDose-LimitingEligibility DeterminationFundingGrantHsp 90 InhibitionInpatientsInstitutionLeukemiaMalignant NeoplasmsMaximum Tolerated DoseNumbersOutpatientsPediatric OncologyProgressive Disease
Grant awards (4)
Post Graduate Training in Pediatric Oncology$356,968
T32 · FY2015 · CA · contact PI
17-AAG IN PEDIATRIC PATIENTS WITH RECURRENT/REFRACTORY MALIGNANCIES$370
M01 · FY2007 · RR · contact PI
17-AAG IN PEDIATRIC PATIENTS WITH RECURRENT/REFRACTORY MALIGNANCIES$1,486
M01 · FY2006 · RR · contact PI
17-AAG IN PEDIATRIC PATIENTS WITH RECURRENT/REFRACTORY MALIGNANCIES$29,877
M01 · FY2005 · RR